Trial document

drksid header

DRKS-ID: DRKS00016066

Trial Description

start of 1:1-Block title

Title

Early Palliative Care for Patients with Glioblastoma; a randomized phase lll clinical trial

end of 1:1-Block title

start of 1:1-Block acronym

Trial Acronym

EPCOG

end of 1:1-Block acronym

start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url

start of 1:1-Block public summary

Brief Summary in Lay Language

This is a multicenter, randomized, confirmatory, phase III, controlled, clinical parallel group study investigating the effect of early integration of palliative care (EIPC) for patients with glioblastoma disease. The study is conducted by the Center for Palliative Medicine at the University Hospital of Cologne.

Early integration of palliative care (EIPC) in systemic tumor diseases can, among other things, have a positive effect on the quality of life and depressivity of patients, avoid aggressive therapies at the end of life, prolong the lifespan and reduce the burden on relatives/related person (Bakitas et al., 2015; Zimmermann et al., 2014; Temel et al., 2010).

These advantages of EIPC have already been demonstrated for various tumor entities. However, data on the effect of EIPC in patients with glioblastoma (GBM), an extraordinarily malignant brain tumor that can be regarded as a model for rapidly progressive malignant tumors with a wide range of new psychiatric symptoms and psychosocial challenges, do not yet exist.

Therefore, in this study we want to investigate the efficacy of EIPC in GBM patients with very different needs compared to patients with systemic tumor diseases, in medical disciplines (neurooncology, neurosurgery) who are little experienced with palliative medicine and under consideration of feasibility within the German health care system. The study also investigates the effect of EIPC regarding the burden on relatives/related person, which will also be included in this study.

end of 1:1-Block public summary

start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

To determine the efficacy of proactive early specialized palliative care in patients with glioblastoma to improve quality of life.

end of 1:1-Block scientific synopsis

start of 1:1-Block organizational data

Organizational Data

DRKS-ID: DRKS00016066
Date of Registration in DRKS: 2019/04/29
Date of Registration in Partner Registry or other Primary Registry: [---]*
Investigator Sponsored/Initiated Trial (IST/IIT): yes
Ethics Approval/Approval of the Ethics Committee: Approved
(leading) Ethics Committee No.: 19-1024, Ethik-Kommission der Medizinischen Fakultät der Universität zu Köln

end of 1:1-Block organizational data

start of 1:n-Block secondary IDs

Secondary IDs

[---]*

end of 1:n-Block secondary IDs

start of 1:N-Block indications

Health Condition or Problem studied

ICD10: C71.9 - Malignant neoplasm: Brain, unspecified

end of 1:N-Block indications

start of 1:N-Block interventions

Interventions/Observational Groups

Arm 1: Control Group: Patients will receive “optimized” standard care. This includes regular visits to the neurosurgery -in Bonn also to the Neurooncology- outpatient clinic every 3 months (+/- 1 week) with treatment and routine assessment following international standards. In addition, the “optimization” will be that patients’ Quality of Life will regularly be measured using the FACT-Br questionnaire.
Arm 2: Intervention group: in addition to the "optimized" standard care, patients will regularly receive structured contacts (for 12 months) with specialized palliative care, independent of current needs (“proactive”). The intervention will be contducted by a specialized palliative care team consisting of a palliative care physician and a palliative care social worker.

end of 1:N-Block interventions

start of 1:1-Block design

Characteristics

Study Type: Interventional
Study Type Non-Interventional: [---]*
Allocation: Randomized controlled trial
Blinding: Blinded
Who is blinded: assessor
Control: Active control (effective treament of control group)
Purpose: Supportive care
Assignment: Parallel
Phase: III
Off-label Drug use: N/A

end of 1:1-Block design

start of 1:1-Block primary endpoint

Primary Outcome

Change in the quality of life after 6 months compared to the beginning of proactive early specialized palliative care.

end of 1:1-Block primary endpoint

start of 1:1-Block secondary endpoint

Secondary Outcome

Changes in patients’ Quality of Life measured by the from baseline to 12 months (end of intervention), 18 months, 24 months of follow-up (to evaluate maintenance/sustainability of effect), patients’ palliative care needs, patients’ depression and anxiety, patients’ cognitive impairment, caregiver burden, each outcome measurement being validated and cost-effectiveness from the societal perspective including direct medical and direct non-medical costs.

end of 1:1-Block secondary endpoint

start of 1:n-Block recruitment countries

Countries of Recruitment

DE: Germany

end of 1:n-Block recruitment countries

start of 1:n-Block recruitment locations

Locations of Recruitment

University Medical Center Klinik für Allgemeine Neurochirurgie der Uniklinik Köln sowie das MVZ Neurochirurgie der Uniklinik Köln, Köln
University Medical Center Sektion Klinische Neuroonkologie der Klinik und Poliklinik der Neurologie am Universitätsklinikum Bonn und Klinik für Neurochirurgie, Bonn
University Medical Center Klinik für Neurochirurgie, RWTH Aachen
University Medical Center Neurochirurgische Klinik und Poliklinik der LMU, München
University Medical Center Klinik für Neurochirurgie im Neurozentrum des Universitätsklinikums Freiburg, Freiburg im Breisgau

end of 1:n-Block recruitment locations

start of 1:1-Block recruitment

Recruitment

Planned/Actual: Actual
(Anticipated or Actual) Date of First Enrollment: 2019/05/10
Target Sample Size: 214
Monocenter/Multicenter trial: Multicenter trial
National/International: National

end of 1:1-Block recruitment

start of 1:1-Block inclusion criteria

Inclusion Criteria

Gender: Both, male and female
Minimum Age: 18 Years
Maximum Age: no maximum age

end of 1:1-Block inclusion criteria

start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

-Patients with newly diagnosed Glioblastoma (histologically confirmed by biopsy or resection) within 4 weeks of diagnosis
-Patients with recurrent Glioblastoma within 4 weeks after diagnosis of relapse
-Eastern Cooperative Oncology Group (ECOG) Scale: 0-2
-Age ≥ 18 years
-ability to understand, read and respond to the German language
-ability to give written consent

Relatives:

-Person (relative or other closely acquainted person) of particular importance to the patient, i.e. living together or in personal contact with the patient at least twice a week. (Caution: Patients may also be included if such a person does not exist.)
-Eastern Cooperative Oncology Group (ECOG) Scale: 0-2
-Age ≥ 18 years
-ability to understand, read and respond to the German language
-ability to give written consent

end of 1:1-Block inclusion criteria add

start of 1:1-Block exclusion criteria

Exclusion Criteria

Patients and relatives:

-Refusal to adhere to the study protocol
-legal incapacity
-prolonged use of drugs or alcohol or psychiatric disease which, in the opinion of the investigator, makes the patient or relative unsuitable for participation in the study
-Any dependence on the investigators or employed by the sponsor or investigator.
-legal or official placement in an institution

end of 1:1-Block exclusion criteria

start of 1:n-Block addresses

Addresses

Primary Sponsor
start of 1:1-Block address primary-sponsor
- Universität zu Köln
- Albertus-Magnus-Platz
- 50923 Köln
- Germany
end of 1:1-Block address primary-sponsor

start of 1:1-Block address contact primary-sponsor
- Telephone: [---]*
- Fax: [---]*
- E-mail: [---]*
- URL: [---]*
end of 1:1-Block address contact primary-sponsor
Contact for Scientific Queries
start of 1:1-Block address scientific-contact
- Uniklinik Köln,Zentrum für Palliativmedizin
- Ms. PD Dr. med. Heidrun Golla
- Kerpener Str. 62
- 50937 Köln
- Germany
end of 1:1-Block address scientific-contact

start of 1:1-Block address contact scientific-contact
- Telephone: 0049 0221 478 3368
- Fax: [---]*
- E-mail: heidrun.golla at uk-koeln.de
- URL: [---]*
end of 1:1-Block address contact scientific-contact
Contact for Public Queries
start of 1:1-Block address public-contact
- Zentrum für PalliativmedizinUniversitätsklinikum Köln
- Ms. Dr. rer. nat. Charlotte Nettekoven
- Kerpener Straße 62
- 50937 Köln
- Germany
end of 1:1-Block address public-contact

start of 1:1-Block address contact public-contact
- Telephone: 0049 (0)221 478 32050
- Fax: 0049 (0)221 478 82825
- E-mail: charlotte.nettekoven at uk-koeln.de
- URL: [---]*
end of 1:1-Block address contact public-contact

end of 1:n-Block addresses

start of 1:n-Block material support

Sources of Monetary or Material Support

Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)
start of 1:1-Block address materialSupport
- Bundesministerium für Bildung und Forschung Dienstsitz Bonn
- Heinemannstr. 2
- 53175 Bonn
- Germany
end of 1:1-Block address materialSupport

start of 1:1-Block address contact materialSupport
- Telephone: [---]*
- Fax: [---]*
- E-mail: [---]*
- URL: http://www.bmbf.de
end of 1:1-Block address contact materialSupport

end of 1:n-Block material support

start of 1:1-Block state

Status

Recruitment Status: Recruiting ongoing
Study Closing (LPLV): [---]*

end of 1:1-Block state

start of 1:n-Block publications

Trial Publications, Results and other Documents

[---]*

end of 1:n-Block publications

* This entry means the parameter is not applicable or has not been set.